Comparison of Comorbid Conditions Between Cancer Survivors and Age-Matched Patients Without Cancer.
Abstract Background: Cancer survivors suffer from many comorbid conditions even after the cure of their cancers beyond 5 years. We explored the differences in the association of comorbid conditions between the cancer survivors and patients without cancer. Methods: Electronic medical records of 280 adult cancer survivors and 280 age-matched patients without cancer in our suburban internal medicine office were reviewed. Results: Mean age of the cancer survivors was 72.5 ± 13.1 years, and the age of the patients without cancer was 72.5 ± 12.8 years. The number of male cancer survivors was sign...
Source: Clinical Prostate Cancer - November 15, 2018 Category: Cancer & Oncology Authors: Roy S, Vallepu S, Barrios C, Hunter K Tags: J Clin Med Res Source Type: research

A bilingual, Internet-based, targeted advertising campaign for prostate cancer clinical trials: Assessing the feasibility, acceptability, and efficacy of a novel recruitment strategy.
Conclusions: Our study demonstrates that an Internet-based clinical trial matching tool that is advertised using a targeted Internet-based campaign can provide an effective means to reach diverse, low-literacy patients. When implemented at scale and over a longer duration, such interventions may help increase trial participation among underrepresented populations. PMID: 30272035 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - October 3, 2018 Category: Cancer & Oncology Authors: Kaplan CP, Siegel A, Leykin Y, Palmer NR, Borno H, Bielenberg J, Livaudais-Toman J, Ryan C, Small EJ Tags: Contemp Clin Trials Commun Source Type: research

Expressional profiling and clinical relevance of RNase κ in prostate cancer: a novel indicator of favorable progression-free survival.
CONCLUSIONS: RNase κ is a biomarker of favorable prognosis in CaP, which is significantly associated with less advanced and aggressive disease, as well as with enhanced PFS. PMID: 30054827 [PubMed - indexed for MEDLINE] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - October 1, 2018 Category: Cancer & Oncology Authors: Kladi-Skandali A, Mavridis K, Scorilas A, Sideris DC Tags: J Cancer Res Clin Oncol Source Type: research

Second malignancy in non-small cell lung cancer (NSCLC): prevalence and overall survival (OS) in routine clinical practice.
CONCLUSIONS: Prior or synchronous second malignancies are common at diagnosis of NSCLC. The sites reflect the high proportion of smokers in the population. The earlier stage of NSCLC with a second malignancy might be attributed to chance finding of NSCLC during follow-up. The second malignancy does not affect OS of NSCLC. Therefore, the exclusion of patients with second malignancies from NSCLC trials should be reconsidered. PMID: 30062488 [PubMed - indexed for MEDLINE] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - October 1, 2018 Category: Cancer & Oncology Authors: Faehling M, Schwenk B, Kramberg S, Fallscheer S, Leschke M, Sträter J, Eckert R Tags: J Cancer Res Clin Oncol Source Type: research

National and subnational mortality of urological cancers in Iran, 1990-2015.
CONCLUSIONS: In conclusion, despite disparities among different provinces, overall mortality rate of urological cancers decreased significantly since 1990s in Iran. PMID: 30270510 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - October 1, 2018 Category: Cancer & Oncology Authors: Pishgar F, Amini E, Gohari K, Aminorroaya A, Sheidaei A, Rostamabadi Y, Ebrahimi H, Yoosefi M, Naderimagham S, Rezaei N, Modirian M, Namazi Shabestari A, Kompani F, Farzadfar F Tags: Asia Pac J Clin Oncol Source Type: research

Redesigning Prostate Cancer Screening Strategies to Reduce Overdiagnosis.
PMID: 30274977 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - October 1, 2018 Category: Cancer & Oncology Authors: Vickers AJ Tags: Clin Chem Source Type: research

Microbial diversity in infections of patients with medication-related osteonecrosis of the jaw.
CONCLUSION: The bacteria from the submucosal areas and the bottom of the infected bone presented comparable susceptibility to the common antibiotics regimes. Streptococcus spp., Prevotella spp., and Veillonella spp. present a high abundance in MRONJ lesions beside Actinomyces spp. The MRONJ lesions bottom is in many cases not infected by Actinomyces spp. CLINICAL RELEVANCE: The removal of the necrotic bone reduces the variety of bacteria found in MRONJ lesions, in particular at the bottom of the lesion. PMID: 30276516 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - October 1, 2018 Category: Cancer & Oncology Authors: Zirk M, Wenzel C, Buller J, Zöller JE, Zinser M, Peters F Tags: Clin Oral Investig Source Type: research

Radionuclide Therapy for Bone Metastases: Utility of Scintigraphy and PET Imaging for Treatment Planning.
Abstract The skeleton is a common site for cancer metastases. Bone metastases are a major cause of morbidity and mortality and associated with pain, pathologic fractures, spinal cord compression, and decreased survival. Various radionuclides have been used for pain therapy. Recently, an α-emitter has been shown to improve overall survival of patients with bone metastases from castration-resistant prostate cancer and was approved as a therapeutic agent. The aim of this article is to provide an overview regarding state of the art radionuclide therapy options for bone metastases, with focus on the role of PET i...
Source: Clinical Prostate Cancer - September 18, 2018 Category: Cancer & Oncology Authors: Ahmadzadehfar H, Essler M, Rahbar K, Afshar-Oromieh A Tags: PET Clin Source Type: research

Incidental discovery of mucinous adenocarcinoma of the prostate following transurethral resection of the prostate: A report of two cases and a literature review.
Abstract Mucinous carcinoma is an unusual subtype of prostate cancer. In particular, mucinous adenocarcinomas identified following transurethral resection of the prostate (TURP) are extremely rare. The present study conducted are retrospective analysis of two cases of mucinous carcinoma of the prostate, which were incidentally diagnosed following histological examination of the specimens obtained by TURP. The pathological findings, treatment regimen and clinical course of the two cases were reviewed. One of the patients, whose surgical specimen stained positive for carcinoembryonic antigen (CEA) and negative for p...
Source: Clinical Prostate Cancer - September 16, 2018 Category: Cancer & Oncology Authors: Zhang L, Zhang L, Chen M, Fang Q Tags: Mol Clin Oncol Source Type: research

Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal.
PMID: 30209857 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - September 15, 2018 Category: Cancer & Oncology Authors: Hofer MD Tags: Fundam Clin Pharmacol Source Type: research

High-Risk Localized Prostate Cancer: How Important Is the Addition of Brachytherapy to External-Beam Radiotherapy?
PMID: 30212300 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - September 13, 2018 Category: Cancer & Oncology Authors: Gomez-Iturriaga A, Crook J Tags: J Clin Oncol Source Type: research

Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions. There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer...
Source: Clinical Prostate Cancer - September 12, 2018 Category: Cancer & Oncology Authors: Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A Tags: CA Cancer J Clin Source Type: research

Endothelial cells promote metastasis of prostate cancer by enhancing autophagy.
CONCLUSIONS: Together, our data establish the function for endothelial cells in tumor metastasis and propose new drug target for mCRPC. PMID: 30200999 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - September 10, 2018 Category: Cancer & Oncology Authors: Zhao R, Bei X, Yang B, Wang X, Jiang C, Shi F, Wang X, Zhu Y, Jing Y, Han B, Xia S, Jiang Q Tags: J Exp Clin Cancer Res Source Type: research

Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma.
Abstract Painful osseous metastasis resulting from castration-resistant prostate carcinoma is a common clinical problem. Historically, nuclear medicine offered several palliative beta-emitting radiopharmaceuticals targeting the skeleton with the goal of decreasing pain. However, these have largely been replaced by the alpha-emitting agent radium (Ra). Ra received Food and Drug Administration approval in 2013 for the treatment of metastatic castration-resistant prostate cancer with symptomatic bone metastases without visceral metastases. Ra offers an improved therapeutic profile due to its alpha-particle emissions ...
Source: Clinical Prostate Cancer - September 10, 2018 Category: Cancer & Oncology Authors: Wale DJ, Viglianti BL, Gross MD, Ferretti A, Rubello D, Wong KK Tags: Am J Clin Oncol Source Type: research

There Is Now Compelling Evidence to Further Evaluate Lower Doses of Abiraterone Acetate in Men With Metastatic Prostate Cancer: It Should Be Safer, May Be as Effective and Less Expensive.
PMID: 30188787 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - September 6, 2018 Category: Cancer & Oncology Authors: Velho PI, Eisenberger MA Tags: J Clin Oncol Source Type: research

Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy.
Abstract Despite the success of T cell checkpoint blockade against melanoma, many "cold" tumors such as prostate cancer remain unresponsive. We find that hypoxic zones are prevalent across pre-clinical prostate cancer and resist T cell infiltration even in the context of CTLA-4 and PD-1 blockade. We show that the hypoxia-activated prodrug TH-302 reduces or eliminates hypoxia in these tumors. Combination therapy with this hypoxia-prodrug and checkpoint blockade cooperate to cure more than 80% of TRAMP-C2 prostate tumors. Immunofluorescence imaging shows that TH-302 drives an influx of T cells into hypoxic...
Source: Clinical Prostate Cancer - September 6, 2018 Category: Cancer & Oncology Authors: Jayaprakash P, Ai M, Liu A, Budhani P, Bartkowiak T, Sheng J, Ager CR, Nicholas C, Jaiswal AR, Sun Y, Shah K, Balasubramanyam S, Li N, Wang G, Ning J, Zal A, Zal T, Curran MA Tags: J Clin Invest Source Type: research

The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2F5 and PFTK1.
CONCLUSION: These data highlight an important role for miR-1-3p in the regulation of proliferation and cell cycle in the molecular etiology of PCa and indicate the potential for miR-1-3p in applications furthering PCa prognostics and therapeutics. PMID: 30185212 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - September 5, 2018 Category: Cancer & Oncology Authors: Li SM, Wu HL, Yu X, Tang K, Wang SG, Ye ZQ, Hu J Tags: J Exp Clin Cancer Res Source Type: research

Sentinel node evaluation in prostate cancer.
Abstract Sentinel lymph node (SLN) based pelvic lymph node dissection (PLND) in prostate cancer (PCa) is appealing over the time, cost and morbidity classically attributed to conventional PLND during radical prostatectomy. The initial report of feasibility of the SLN concept in prostate cancer was nearly 20 years ago. However, PLND based on the SLN concept, either SLN biopsy of a single node or targeted SLN dissection of multiple nodes, is still considered investigational in PCa. To better appreciate the challenges, and potential solutions, associated with SLN-based PLND in PCa, this review will discuss the r...
Source: Clinical Prostate Cancer - September 5, 2018 Category: Cancer & Oncology Authors: Narayanan R, Wilson TG Tags: Clin Exp Metastasis Source Type: research

Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline.
Abstract Purpose In April 2017, the American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology released a joint evidence-based practice guideline on clinically localized prostate cancer. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. Methods The Clinically Localized Prostate Cancer guideline was reviewed for developmental rigor by methodologists. An ASCO Expert Panel then reviewed the content and the recommendations. Results Th...
Source: Clinical Prostate Cancer - September 5, 2018 Category: Cancer & Oncology Authors: Bekelman JE, Rumble RB, Chen RC, Pisansky TM, Finelli A, Feifer A, Nguyen PL, Loblaw DA, Tagawa ST, Gillessen S, Morgan TM, Liu G, Vapiwala N, Haluschak JJ, Stephenson A, Touijer K, Kungel T, Freedland SJ Tags: J Clin Oncol Source Type: research

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS Abstract BACKGROUND: Understanding the integrated immunogenomic landscape of advanced prostate cancer (APC) could impact stratified treatment selection. METHODS: Defective mismatch repair (dMMR) status was determined by either loss of mismatch repair protein expression on IHC or m...
Source: Clinical Prostate Cancer - September 4, 2018 Category: Cancer & Oncology Authors: Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke Tags: J Clin Invest Source Type: research

Cone beam CT for QA of synthetic CT in MRI only for prostate patients.
on LE Abstract PURPOSE: Magnetic resonance imaging (MRI)-only radiotherapy is performed without computed tomography (CT). A synthetic CT (sCT) is used for treatment planning. The aim of this study was to develop a clinically feasible quality assurance (QA) procedure for sCT using the kV-cone beam CT (CBCT), in an MRI-only workflow for prostate cancer patients. MATERIAL AND METHOD: Three criteria were addressed; stability in Hounsfield Units (HUs), deviations in HUs between the CT and CBCT, and validation of the QA procedure. For the two first criteria, weekly phantom measurements were performed. For the third...
Source: Clinical Prostate Cancer - September 4, 2018 Category: Cancer & Oncology Authors: Palmér E, Persson E, Ambolt P, Gustafsson C, Gunnlaugsson A, Olsson LE Tags: J Appl Clin Med Phys Source Type: research

NCCN Asia Consensus Statement prostate cancer.
Abstract The National Comprehensive Cancer Network, an NPO organization comprised of university hospitals and cancer centers in the US. The publication of clinical practice guidelines on the treatment, diagnosis, prevention and screening is one of important activities. Background factors of prostate cancer patients, such as the prevalence, age at the diagnosis and mortality are markedly different between Western countries and Asia. Thus, various factors should be taken into consideration at the treatment choice for individual patients. Experts from Asian countries were published as the Asia Consensus Statement. In...
Source: Clinical Prostate Cancer - September 4, 2018 Category: Cancer & Oncology Authors: Hinotsu S, Namiki M, Ozono S, Akaza H Tags: Jpn J Clin Oncol Source Type: research

Corosolic acid, a natural triterpenoid, induces ER stress-dependent apoptosis in human castration resistant prostate cancer cells via activation of IRE-1/JNK, PERK/CHOP and TRIB3.
CONCLUSION: Our data demonstrated, for the first time, that CA might represent a novel drug candidate for the development of an anti-CRPC therapy. PMID: 30176898 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - September 3, 2018 Category: Cancer & Oncology Authors: Ma B, Zhang H, Wang Y, Zhao A, Zhu Z, Bao X, Sun Y, Li L, Zhang Q Tags: J Exp Clin Cancer Res Source Type: research

Immune checkpoint inhibitors for urothelial carcinoma.
Abstract Urothelial carcinoma (UC), originating in the bladder or upper urinary tract, is the most common histological type of cancer. Currently, platinum-based cytotoxic chemotherapy is the standard treatment for metastatic UC (mUC) and the preferred treatment option in the perioperative (neoadjuvant and/or adjuvant) setting of muscle invasive bladder cancer (MIBC). In addition, intravesical bacillus Calmette-Guerin immunotherapy or chemotherapy is applied as the adjuvant therapeutic option in non-muscle invasive bladder cancer (NMIBC) after transurethral resection, to prevent recurrence and progression. In recen...
Source: Clinical Prostate Cancer - September 1, 2018 Category: Cancer & Oncology Authors: Kim HS, Seo HK Tags: Investig Clin Urol Source Type: research

Changes in health-related quality of life after radical prostatectomy for prostate cancer: A longitudinal cohort study in Korea.
Conclusions: Urinary outcomes and sexual outcomes had not returned to baseline at 12 months. Recovery of sexual function was significantly greater in patients who underwent robotic surgery. Only recovery of urinary function was significantly associated with overall satisfaction 12 months after radical prostatectomy in this cohort of Korean men. PMID: 30182076 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - September 1, 2018 Category: Cancer & Oncology Authors: Pak S, Kim M, Ahn H Tags: Investig Clin Urol Source Type: research

Prostate cancer leading to monoclonal gammopathy of undetermined significance: A case report.
Abstract Prostate cancer is one of the most common cancer types, affecting millions of individuals worldwide. The present study reported two cases of metastatic prostate cancer presenting with newly diagnosed monoclonal gammopathy of undetermined significance (MGUS). To the best of our knowledge, prostate cancer leading to MGUS has not been documented previously. MGUS is generally thought to be benign and has been demonstrated to convert into multiple myeloma (MM), as well as other lymphoproliferative disorders. Due to the high mortality rate associated with MM, further studies are required to confirm and clarify ...
Source: Clinical Prostate Cancer - August 30, 2018 Category: Cancer & Oncology Authors: Jehangir W, Tulpule S, Sanabria F, Bhatt H, Zafar S, Osman M, Enakuaa S, Yousif A Tags: Mol Clin Oncol Source Type: research

Oxidative stress marker 8-hydroxyguanosine is more highly expressed in prostate cancer than in benign prostatic hyperplasia.
Abstract Oxidative stress is a primary cause of vascular endothelial damage. In the prostate, ischemia increases the levels of reactive oxygen species, growth factors and cytokines, and induces the development of angiogenesis, which results in cancer progression. The expression levels of an oxidative stress marker, 8-hydroxyguanosine (8-OHdG), were compared between prostate cancer and non-neoplastic prostate tissues. A prostate tissue microarray composed of 10 cases of prostatic adenocarcinoma and 70 cases of benign prostatic hyperplasia was immunohistochemically stained for 8-OHdG. All cases expressed 8-OHdG. The...
Source: Clinical Prostate Cancer - August 17, 2018 Category: Cancer & Oncology Authors: Ohtake S, Kawahara T, Ishiguro Y, Takeshima T, Kuroda S, Izumi K, Miyamoto H, Uemura H Tags: Mol Clin Oncol Source Type: research

Short-term Toxicity of High Dose Rate Brachytherapy in Prostate Cancer Patients with Inflammatory Bowel Disease.
DISCUSSION: This small, prospective case series suggests that, in the short term, HDR brachytherapy is safe and well tolerated in IBD patients. Therefore, IBD should not automatically disqualify patients from, at least, HDR brachytherapy. The reason why these results differ from previous LDR studies possibly reflects the benefit of inverse planning, which more readily achieves rectal dose constraints in HDR brachytherapy. PMID: 30099986 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - August 14, 2018 Category: Cancer & Oncology Authors: Mohammed W, Hoskin P, Henry A, Gomez-Iturriaga A, Robinson A, Nikapota A Tags: Clin Oncol (R Coll Radiol) Source Type: research

Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials.
Abstract PURPOSE: Castration-resistant prostate cancer (CRPC) refers to prostate cancer that has progressed after initial androgen deprivation therapy (ADT). Over the years, treatment strategies for metastatic CRPC (mCRPC) have undergone considerable changes. We performed a network meta-analysis to assess the effectiveness and tolerability of targeted agents for mCRPC. METHODS: We search databases including MEDLINE, EMBASE, and the Cochrane Library through Sep 5, 2017. The major effectiveness outcomes were progression-free survival (PFS) and overall survival (OS). The tolerability outcome was severe adverse e...
Source: Clinical Prostate Cancer - August 7, 2018 Category: Cancer & Oncology Authors: Wang Y, Zhang H, Shen W, He P, Zhou Z Tags: J Cancer Res Clin Oncol Source Type: research

Association between pathologic factors and ERG expression in prostate cancer: finding pivotal networking.
CONCLUSIONS: Evaluating the association between ERG expression and pathologic factors, and identifying the regulatory network and pivotal hub may help to understand the clinical significance of ERG-positive prostate cancer. PMID: 29948147 [PubMed - indexed for MEDLINE] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - August 7, 2018 Category: Cancer & Oncology Authors: Lee SR, Choi YD, Cho NH Tags: J Cancer Res Clin Oncol Source Type: research

Incidental Detection of Tracer Avidity in Liposarcoma on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT.
We describe the case of a 76-year-old man who underwent Ga-labeled PSMA PET/CT for suspicion of prostate cancer. Whole-body PET/CT of whom revealed tracer avidity in lipomatous lesion involving the left sartorius muscle. Histopathologic examination of lesion revealed a well-differentiated liposarcoma. PMID: 30080189 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - August 7, 2018 Category: Cancer & Oncology Authors: Malik D, Mittal BR, Kumar R, Singh H, Bhattacharya A, Singh SK Tags: Clin Nucl Med Source Type: research

MALDI-TOF peptidomic analysis of serum and post-prostatic massage urine specimens to identify prostate cancer biomarkers.
Conclusions: MALDI-TOF/MS serum peptidome profiling was more efficacious with respect to post-prostatic massage urine analysis in discriminating PCa. PMID: 30065622 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - August 3, 2018 Category: Cancer & Oncology Authors: Padoan A, Basso D, Zambon CF, Prayer-Galetti T, Arrigoni G, Bozzato D, Moz S, Zattoni F, Bellocco R, Plebani M Tags: Clin Proteomics Source Type: research

SPOP mutated/ CHD1 deleted lethal prostate cancer and abiraterone sensitivity.
CONCLUSION: SPOP mutated mCRPCs are strongly enriched for CHD1 loss. These tumors appear highly sensitive to abiraterone treatment. PMID: 30068710 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - August 1, 2018 Category: Cancer & Oncology Authors: Boysen G, Nava Rodrigues D, Rescigno P, Seed G, Dolling DI, Riisnaes R, Crespo M, Zafeiriou Z, Sumanasuriya S, Bianchini D, Hunt J, Moloney D, Perez-Lopez R, Tunariu N, Miranda S, Figueiredo I, Ferreira A, Christova R, Gil V, Aziz S, Bertan C, de Oliveira Tags: Clin Cancer Res Source Type: research

Smad4/DPC4.
Abstract Smad4 or DPC4 belongs to a family of signal transduction proteins that are phosphorylated and activated by transmembrane serine-threonine receptor kinases in response to transforming growth factor beta (TGF-β) signaling via several pathways. The gene acts as a tumour suppressor gene and inactivation of smad4/DPC4 is best recognised in pancreatic cancer. However, smad4/DPC4 is also mutated in other conditions and cancers such as juvenile polyposis syndrome with and without hereditary haemorrhagic telangiectasia, colorectal and prostate cancers.Immunohistochemistry for smad4/DPC4 protein is most useful...
Source: Clinical Prostate Cancer - July 31, 2018 Category: Cancer & Oncology Authors: McCarthy AJ, Chetty R Tags: J Clin Pathol Source Type: research

Exosome-mediated transfer of lncRNA PART1 induces gefitinib resistance in esophageal squamous cell carcinoma via functioning as a competing endogenous RNA.
CONCLUSIONS: LncRNA PART1 promotes gefitinib resistance by regulating miR-129/Bcl-2 pathway, and may serve as a therapeutic target for ESCC patients. PMID: 30049286 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 27, 2018 Category: Cancer & Oncology Authors: Kang M, Ren M, Li Y, Fu Y, Deng M, Li C Tags: J Exp Clin Cancer Res Source Type: research

Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming.
Abstract Prostate cancer is an androgen-dependent disease subject to interactions between the tumor epithelia and its microenvironment. Here, we found epigenetic changes in cancer-associated prostatic fibroblasts (CAF) initiated a cascade of stromal-epithelial interactions. This facilitated lethal prostate cancer growth and development of resistance to androgen signaling deprivation therapy (ADT). We identified that a Ras inhibitor, RASAL3, is epigenetically silenced in human prostatic CAF, leading to oncogenic Ras activity driving macropinocytosis-mediated glutamine synthesis. Interestingly, ADT further promoted ...
Source: Clinical Prostate Cancer - July 26, 2018 Category: Cancer & Oncology Authors: Mishra R, Haldar S, Placencio V, Madhav A, Rohena-Rivera K, Agarwal P, Duong F, Angara B, Tripathi M, Liu Z, Gottlieb RA, Wagner S, Posadas EM, Bhowmick NA Tags: J Clin Invest Source Type: research

Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer.
ázaro-Quintela M, Vázquez S Abstract Administration of chemotherapy in prostate cancer depends on patient fitness. In unfit patients, physiological impairment determines the optimum treatment. Although no consensus on assessing patient fitness currently exists, this article proposes an algorithm combining the available information for administering chemotherapy, and in particular docetaxel, in unfit patients. It was constructed by reviewing factors that can influence treatment, such as performance status, taxane-related comorbidities and nutritional status. Geriatric scales for prostate cancer patien...
Source: Clinical Prostate Cancer - July 26, 2018 Category: Cancer & Oncology Authors: Anido-Herranz U, Fernández-Núñez N, Afonso-Afonso J, Santomé-Couto L, Medina-Colmenero A, Fernández-Calvo O, Lázaro-Quintela M, Vázquez S Tags: Clin Transl Oncol Source Type: research

Interleukin-17 promotes metastasis in an immunocompetent orthotopic mouse model of prostate cancer.
Abstract Metastasis of prostate cancer causes substantial morbidity and mortality. The role of chronic inflammatory factors in promoting the development of prostate cancer metastasis remains unexamined due to a lack of immunocompetent animal models. Here we report an orthotopic mouse allograft model of prostate cancer that was used to assess interleukin-17's role in prostate cancer metastasis. A luciferase gene was stably introduced into a mouse prostate cancer cell line MPC3, named as MPC3-luc. MPC3-luc cells were mixed with Matrigel™ and inoculated into C57BL/6 mouse prostates, with recombinant mouse inter...
Source: Clinical Prostate Cancer - July 25, 2018 Category: Cancer & Oncology Authors: Cunningham D, Zhang Q, Liu S, Parajuli KR, Nie Q, Ma L, Zhang A, Chen Z, You Z Tags: Am J Clin Exp Urol Source Type: research

The impact of celecoxib on outcomes in advanced prostate cancer patients undergoing androgen deprivation therapy.
This study explores the effect of celecoxib use on PC survival in VA patients undergoing androgen deprivation therapy (ADT) for advanced PC. We retrospectively examined the association between celecoxib use (defined as duration of medication use ≥180 days) in men with PC being treated with ADT in national VA databases. Patients were diagnosed with PC from 2000-2008 and had follow-up through May 2016. Clinical, pathologic and demographic variables were compared by celecoxib use, using Mann-Whitney U test and Chi-squared tests. Associations between celecoxib use and overall survival (OS), skeletal related events (SRE), an...
Source: Clinical Prostate Cancer - July 25, 2018 Category: Cancer & Oncology Authors: Etheridge T, Liou J, Downs TM, Abel EJ, Richards KA, Jarrard DF Tags: Am J Clin Exp Urol Source Type: research

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer.
Conclusions: Degarelix is effective in the treatment of prostate cancer. Degarelix therapy can also be safely changed to a gonadotropin releasing hormone agonist without any adverse clinical or oncological effects. PMID: 30026950 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 23, 2018 Category: Cancer & Oncology Authors: Asakawa J, Iguchi T, Tamada S, Yasuda S, Ninomiya N, Kato M, Yamasaki T, Ohmachi T, Nakatani T Tags: Basic Clin Androl Source Type: research

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment.
Conclusion Combining enzalutamide with abiraterone acetate and prednisone is not indicated after PSA progression during treatment with enzalutamide alone; hypertension and elevated liver enzymes are more frequent with combination therapy. PMID: 30028657 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 20, 2018 Category: Cancer & Oncology Authors: Attard G, Borre M, Gurney H, Loriot Y, Andresen-Daniil C, Kalleda R, Pham T, Taplin ME, PLATO collaborators Tags: J Clin Oncol Source Type: research

Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K/AKT signaling.
CONCLUSION: Our results unveil a novel mechanism by which miR-133a-3p inhibits bone metastasis of PCa, providing the evidence that miR-133a-3p may serve as a potential bone metastasis marker in PCa, and delivery of agomir-133a-3p may be an effective anti-bone metastasis therapeutic strategy in PCa. PMID: 30021600 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 18, 2018 Category: Cancer & Oncology Authors: Tang Y, Pan J, Huang S, Peng X, Zou X, Luo Y, Ren D, Zhang X, Li R, He P, Wa Q Tags: J Exp Clin Cancer Res Source Type: research

Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis.
CONCLUSIONS: CT-naïve patients treated with AA obtained a better clinical benefit in terms of effectiveness, safety and cost-effectiveness ratio than post-CT patients. The effectiveness outcomes were poorer than those reported previously in the clinical trial setting. PMID: 30022386 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 18, 2018 Category: Cancer & Oncology Authors: Koninckx M, Marco JL, Pérez I, Faus MT, Alcolea V, Gómez F Tags: Clin Transl Oncol Source Type: research

PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.
CONCLUSIONS: Our studies revealed that the synergistic lethality of HDAC and PARP inhibitors resulted from promoting DNA damage and inhibiting HR DNA damage repair pathways, in particular targeting the UHRF1/BRCA1 protein complex. The synergistic lethality of veliparib and SAHA shows great potential for future PCa clinical trials. PMID: 30012171 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 16, 2018 Category: Cancer & Oncology Authors: Yin L, Liu Y, Peng Y, Peng Y, Yu X, Gao Y, Yuan B, Zhu Q, Cao T, He L, Gong Z, Sun L, Fan X, Li X Tags: J Exp Clin Cancer Res Source Type: research

Biochemical Recurrence of Prostate Cancer Presenting as Solitary Testicular Metastasis on 68Ga-Labeled Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography.
BB, Altun GD Abstract Prostate adenocarcinoma (PCa) is the most frequently diagnosed malignancy in the male population, with the most common sites for secondary lesions being the lymph nodes, bones, and lungs. Testicular metastases from PCa are very rare and mostly identified incidentally after therapeutic orchiectomy for advanced PCa or during autopsy. Here we present a case involving a 64-year-old man with biochemical recurrence of castrated oligometastatic PCa that presented as solitary testicular metastasis on Ga-PSMA ligand positron emission tomography/computed tomography. PMID: 30015663 [PubMed - as su...
Source: Clinical Prostate Cancer - July 14, 2018 Category: Cancer & Oncology Authors: Ege Aktas G, Yürüt Çaloğlu V, Akdere H, Tutuğ BB, Altun GD Tags: Clin Nucl Med Source Type: research

Baseline 18F-Fluorocholine PET/CT and bone scan in the outcome prediction of patients treated with radium 223 dichloride.
CONCLUSION: FCH PET/CT and BS had prognostic aim in the prediction of OS. None clinical or imaging variable was able to predict the PFS, probably due to the high rate of progressive disease. PMID: 30006674 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 13, 2018 Category: Cancer & Oncology Authors: García Vicente AM, González García B, Amo-Salas M, García Carbonero I, Cassinello Espinosa J, Gómez-Aldaraví Gutierrez JL, Suarez Hinojosa L, Soriano Castrejón Á Tags: Clin Transl Oncol Source Type: research

A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA.
Conclusions: PCA-specific methylation was detected in both FV and DRE DNA. There was no significant difference in diagnostic accuracy at the 6of19 threshold between DRE and FV urine DNA. The results support the development of a non-invasive diagnostic test to reduce unnecessary biopsies in men with elevated PSA. The test can also provide patients with personalized recommendations based on their own methylation profile. PMID: 29988684 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 11, 2018 Category: Cancer & Oncology Authors: Brikun I, Nusskern D, Decatus A, Harvey E, Li L, Freije D Tags: Clin Epigenetics Source Type: research

Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203.
Conclusion Pelvic IMRT was associated with significantly less GI and urinary toxicity than standard RT from the patient's perspective. PMID: 29989857 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 10, 2018 Category: Cancer & Oncology Authors: Klopp AH, Yeung AR, Deshmukh S, Gil KM, Wenzel L, Westin SN, Gifford K, Gaffney DK, Small W, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Pugh SL, Kachnic LA, Bruner DW Tags: J Clin Oncol Source Type: research

The role of CD133 in cancer: a concise review.
Abstract Despite the abundant ongoing research efforts, cancer remains one of the most challenging diseases to treat globally. Due to the heterogenous nature of cancer, one of the major clinical challenges in therapeutic development is the cancer's ability to develop resistance. It has been hypothesized that cancer stem cells are the cause for this resistance, and targeting them will lead to tumor regression. A pentaspan transmembrane glycoprotein, CD133 has been suggested to mark cancer stem cells in various tumor types, however, the accuracy of CD133 as a cancer stem cell biomarker has been highly controversial....
Source: Clinical Prostate Cancer - July 9, 2018 Category: Cancer & Oncology Authors: Glumac PM, LeBeau AM Tags: Clin Transl Med Source Type: research

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
Conclusion t-SCNC is present in nearly one fifth of patients with mCRPC and is associated with shortened survival. The near-mutual exclusivity with DNA repair alterations suggests t-SCNC may be a distinct subset of mCRPC. Transcriptional profiling facilitates the identification of t-SCNC and novel therapeutic targets. PMID: 29985747 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 9, 2018 Category: Cancer & Oncology Authors: Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, New Tags: J Clin Oncol Source Type: research